Related Experiment Video
Updated: Aug 18, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T
Charles H Cunningham1, Daniel B Vigneron, Malgorzata Marjanska
1Department of Electrical Engineering, Stanford University, California, USA. chuck.cunningham@stanford.edu
Abstract:
Magnetic resonance spectroscopic imaging (MRSI) has proven to be a powerful tool for the metabolic characterization of prostate cancer in patients before and following therapy. The metabolites that are of particular interest are citrate and choline because an increased choline-to-citrate ratio can be used as a marker for cancer. High-field systems offer the advantage of improved spectral resolution as well as increased magnetization. Initial attempts at extending MRSI methods to 3 T have been confounded by the J-modulation of the citrate resonances. A new pulse sequence is presented that controls the J-modulation of citrate at 3 T such that citrate is upright, with high amplitude, at a practical echo time. The design of short (14 ms) spectral-spatial refocusing pulses and trains of nonselective refocusing pulses are described. Phantom studies and simulations showed that upright citrate with negligible sidebands is observed at an echo time of 85 ms. Studies in a human subject verified that this behavior is reproduced in vivo and demonstrated that the water and lipid suppression of the new pulse sequence are sufficient for application in prostate cancer patients.
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies IV: Magnetic Resonance Imaging
NMR Spectrometers: Radiofrequency Pulses and Pulse Sequences

